

慢性疼痛
レポート④

副作用で薬物が使えない強直性脊椎炎患者に脂肪由来幹細胞を静脈投与した有効性

Peng Wang, et al.
Effects and Safety of Allogenic Mesenchymal Stem Cell Intravenous Infusion in Active Ankylosing Spondylitis Patients Who Failed NSAIDs: A 20-Week Clinical Trial
: Cell Transplantation, Vol. 23, pp. 1293-1303, 2014




Figure 5. Graphic representation of variations of the efficacy evaluation indices after MSC IV infusion. (A) The mean ASDAS-CRP score decreased from 3.6 ± 0.6 to 2.4 ± 0.5 , which was its minimum after four infusions of MSCs, and then increased slowly (after 12 weeks) to 3.2 ± 0.8 . Similar variations were found in the mean total back pain, patient global, stiffness and fatigue score (B), as well as the mean CRP value (C) and BASFI, BASMI (D). As shown in the graph, the mean ESR value had a smaller rangeability compared to the indices above and reached its minimum at the eighth week (C). * $p < 0.05$ and ** $p < 0.01$. Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; ESR, Erythrocyte Sedimentation Rate; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index.